中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

20 records (took 0.021 seconds)

    PROCESS FOR PREPARING PYRROLIDONES
    1.
    发明授权
    PROCESS FOR PREPARING PYRROLIDONES 失效

    公开(公告)号：KR790001252B1

    公开(公告)日：1979-09-18

    申请号：KR750001918

    申请日：1975-08-28

    Applicant: HOECHST AG

    Inventor： GERHARD BECK ,  WIHELM BARTMANN ,  MILOS BABEI ,  KLAUS KUEHLEIN ,  DIETER-BERND REUSCHLING

    Abstract: Prostaglandine-like title compds. (I; R1 = C1-6 straight or side chain alkyl, 3-5 member ring cycloalkyl; R2 = C1-4 straight or side chain alkyl ; R3 = C1-5 O-or S-alkyl, C1-3 alkyl substituted phenoxy, halogen, C1-10 straight or side chain alkyl; n = 2,3 ; m = 1,2) were prepd. from Me itaconate and RNH2, CH2:CH(CH2)si-hal, (R4)3 P:CH-(CH2)SCOMe (R4 = C1-4 alkyl, Ph; Me = alk. metal) and (RA5)2-P(O)-CH2CO-R3(R5 = C1-4 straight chain alkyl) in 9 steps.

    NOVEL PROSTAGLANDIN ANALOGOUS COMPOUNDS AND PROCESS FOR PREPARING THEM
    7.
    发明专利
    NOVEL PROSTAGLANDIN ANALOGOUS COMPOUNDS AND PROCESS FOR PREPARING THEM 未知

    公开(公告)号：ZA757872B

    公开(公告)日：1976-11-24

    申请号：ZA757872

    申请日：1975-12-19

    Applicant: HOECHST AG

    Inventor： BECK GERHARD ,  GERHARD BECK ,  LERCH ULRICH ,  ULRICH LERCH ,  SEEGER KARL ,  KARL SEEGER ,  TEUFEL HERMANN ,  HERMANN TEUFEL

    IPC: C07C67/00 ,  C07C401/00 ,  C07C405/00 ,  C07D307/935 ,  C07D309/12 ,  C07F9/38 ,  C07F9/40 ,  C07C ,  A61K

    Abstract: Prostaglandin analogues of formula (I) in the natural, optically active configuration or as racemic cpds.: (where R1 + R2 is O, or one of R1 and R2 is H and the other is OH; one of R3 and R4 is H and the other is OH; is 1-5C straight or branched alkyl, or phenyl or benzyl opt. mono- di- or tri-substd. in the nucleus by halogen, CF3, OH, 1-4C alkyl and/or 1-4C alkoxy; R5, when X is 1-5C alkyl, is a diphenyl ether gp. opt. mono- di- or tri-substd. in either or both nuclei by halogen, CF3, OH, 1-4C alkyl and/or 1-4C alkoxy or a phenoxy-(2-5 C straight chain or 3-6C branched chain alkyl) opt. mono-di- or tri-substd. in the nucleus by halogen, CF3, OH, 1-4C alkyl and/or 1-4C alkoxy, or, when X is opt. substd. phenyl, a benzyl residue opt. mono- di- or tri-substd. in the nucleus by halogen, CF3, OH, 1-4C alkyl and/or 1-4C alkoxy, or, when X is opt. substd. benzyl, a phenyl residue opt. mono-, di- or tri-substd. by halogen, CF3, OH, 1-4C alkyl and/or 1-4C alkoxy; and the C-atoms in the 5- and 6-positions and the 13- and 14-positions are all linked by single bonds or all linked by double bonds), e.g. 9-oxo-11 alpha, 15-dihydroxy-16-methyl-16-(3-chloro-4-(4-chlorophenoxy)-phenoxy)-- 5-cis-13-trans-tetranorprostadienoci acid, their physiologically tolerable salts with organic and inorganic bases, and their esters with 1-8C aliphatic, cycloaliphatic and araliphatic alcohols are new. (I) can be used as pharmaceuticals with hypotensive, diuretic, antithrombotic labour-inducing, abortifacient, contraceptive, gastric secretion inhibiting, antiulcer and antiasthmatic activity. They are particularly useful as contraceptives for use in humans and as agents for synchronising oestrus in various animal species. They are more potent and longer-acting than natural prostaglandins.

Patent Agency Ranking